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Abstract
Background: Some array comparative genomic hybridisation (array CGH) platforms require a
minimum of micrograms of DNA for the generation of reliable and reproducible data. For studies
where there are limited amounts of genetic material, whole genome amplification (WGA) is an
attractive method for generating sufficient quantities of genomic material from miniscule amounts
of starting material. A range of WGA methods are available and the multiple displacement
amplification (MDA) approach has been shown to be highly accurate, although amplification bias
has been reported. In the current study, WGA was used to amplify DNA extracted from whole
blood. In total, six array CGH experiments were performed to investigate whether the use of
whole genome amplified DNA (wgaDNA) produces reliable and reproducible results. Four
experiments were conducted on amplified DNA compared to unamplified DNA and two
experiments on unamplified DNA compared to unamplified DNA.
Findings: All the experiments involving wgaDNA resulted in a high proportion of losses and gains
of genomic material. Previously, amplification bias has been overcome by using amplified DNA in
both the test and reference DNA. Our data suggests that this approach may not be effective, as
the gains and losses introduced by WGA appears to be random and are not reproducible between
different experiments using the same DNA.
Conclusion: In light of these findings, the use of both amplified test and reference DNA on CGH
arrays may not provide an accurate representation of copy number variation in the DNA.
Background
Comparative genomic hybridisation (CGH) was devel-
oped to detect deletions, duplications and amplifications
in genomic DNA by producing a map of DNA sequence
copy number against its chromosomal location [1]. This
process can require several micrograms of DNA and in sit-
uations where there are limited quantities of genomic
DNA (gDNA) available for experimentation the utility of
whole genome amplification (WGA) is very attractive for
genetic studies.
The multiple displacement amplification (MDA) WGA
method replicates the genome isothermally using random
hexamer primers and DNA polymerase (e.g. Phi29) fol-
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lowed by strand-displacement [2]. Studies on Phi29 have
reported almost complete genome coverage with little
amplification bias and high accuracy [2,3], which is
thought to be due to the high-quality proof reading activ-
ity of the enzyme [4]. Nevertheless, amplification bias has
been reported [5,6], which may be caused by Phi29 repli-
cating one chromosome preferentially in the initial stages
of the reaction [7]. It also appears that the method does
not replicate highly repetitive centromeric regions effec-
tively [8]. High concordance rates and reproducibility in
single nucleotide polymorphism (SNP) genotyping stud-
ies have been reported between whole genome amplified
DNA (wgaDNA) and gDNA [5,9-11] but controversial
results have been reported [12]. There is in addition data
to suggest that WGA creates imbalanced amplification of
alleles resulting in mistyping of heterozygote genotypes as
homozygotes [5,13], which is a result of unequal effi-
ciency in the amplification of the two alleles.
The uniformity of chromosome coverage of WGA via the
MDA method has been tested using CGH arrays, and a sig-
nificant amplification bias between different genomic
sequences, particularly at the ends of chromosomes, has
been reported [14]. Lage et al. [14] suggests that this prob-
lem can be overcome by using wgaDNA in both reference
and test sample, while others have overcome the problem
by using additional statistical methods to avoid exclusion
of genomic regions affected by amplification distortion
and high variability [15]. It has also been demonstrated
that wgaDNA compared to gDNA did not induce signifi-
cant amplification bias when compared by quantitative
PCR, SNP genotyping, southern blotting, restriction frag-
ment length polymorphism (RFLP) analysis and CGH [3],
even though there was an indication of loss of the repeti-
tive centromeric regions.
Because of the necessity for the use of wgaDNA in our
project, and the inconsistency between results reported on
wgaDNA and CGH arrays, whole genome CGH experi-
ments were conducted utilising commercial microarrays
from Spectral Genomics to determine the effect of using
wgaDNA compared to gDNA.
Methods
DNA samples
Human female and male pooled gDNA (Promega) was
used to optimise the CGH method. DNA was extracted
from whole blood from 2 controls (healthy female and
male) and 1 patient in remission from acute lymphoblas-
tic leukaemia (ALL) by the salt-precipitation method [16].
Whole genome amplification (WGA)
Multiple displacement amplification (MDA) was per-
formed using the GenomiPhi kit (GE Healthcare Life Sci-
ences) and fragmentation, adaptor-ligation PCR (FLP)
was performed with GenomePlex (Rubicon Genomics
Inc.) according to the manufacturer's instructions (see
protocols in additional file 1), with minor variation; the
ethanol precipitation step at the end was omitted, as the
DNA was purified with a DNA Clean and Concentrator kit
(Zymo Research) before use on the CGH arrays.
Quantitation of DNA samples
Quant-iT™ DNA assay kit (Molecular Probes Inc) was used
to quantify the concentration of the DNA samples, both
before and after WGA, using a fluorometer: Fluostar
Optima (BMG Labtech Pty Ltd).
Comparative genomic hybridisation (CGH)
The SpectralChip2600™ array consisted of 2632 BAC
clones positioned at approximately 1 Mb intervals
throughout the genome. DNA samples were fragmented
twice using a Branson Sonifier 250 (Branson Ultrasonics
Corporation), before purification with a DNA Clean and
Concentrator™ kit (Zymo Research). DNA labelling with
Cy3- and Cy5-dCTP (Amersham Biosciences) was per-
formed using the BioPrime Labelling Kit (Invitrogen).
DNA labelling, hybridisation and washing of the arrays
was performed as per manufacturers' instructions (see
protocol in additional file 1). Dye-reversal experiments
with reciprocal labelling of the test and reference DNA
were performed for each experiment. A clone was called
abnormal/significant only if observed on both hybridisa-
tions. The arrays were scanned using GenePix 4000B scan-
ner (Axon Instruments, Union City, CA) and the images
analysed using GenePix Pro 3.0 software. The result files
were analysed using Spectralware™ version 2.0 (Spectral
Genomics). The software converts two-colour fluorescent
dye signals into intensity ratio profiles. The different
experiments conducted are described in Table 1.
Results
To validate and optimise the CGH array method, female
and male pooled DNA samples were analysed using the X
chromosome as an internal standard. The data was nor-
malised by global linear regression and the threshold of
significance of ratios was between 0.7–0.8 and 1.2–1.5 in
all experiments. Any clones outside these values were con-
sidered deleted or duplicated if observed in both hybridi-
sations (dye-swap experiments). The database of
Genomic Variants [17] was used to identify common pol-
ymorphisms and single clones were considered clinically
relevant.
The observed number of significant clones gained and lost
can be seen in Table 2 and are listed in additional file 2.
Experiment 1 (pooled female vs. pooled male) showed
complete gain of the X chromosome in the female pooled
DNA sample as well as 21 duplicated and 6 deleted clones
(see Figure 1). All the significant clones were single cloneBMC Research Notes 2008, 1:56 http://www.biomedcentral.com/1756-0500/1/56
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alterations, except for two locations, 6q14 (RP11-343P23
and RP11-79L15) and 7p21.1 (cosIIIA0 and IH3).
For an initial evaluation of the wgaDNA, CGH arrays were
performed using female control wgaDNA vs. female con-
trol gDNA. The control female gDNA sample underwent
two independent WGA reactions using the same method
(GenomiPhi). The first CGH experiment (experiment 2)
resulted in 20 duplicated and 120 deleted clones, while
the second CGH experiment (experiment 3) produced 1
duplicated and 69 deleted clones. Only 23 of the signifi-
cant clones were the same in both experiments (colour
marked in additional file 2). The experiment was repeated
with male control gDNA, using two different WGA meth-
ods (GenomiPhi and GenomePlex), and similar results
were obtained. The first CGH experiment (experiment 4)
resulted in 17 duplicated and 134 deleted clones (see Fig-
ure 2), while the second CGH experiment (experiment 5)
revealed 11 duplicated and 59 deleted clones. Only 16
clones were the same in both experiments (colour marked
in additional file 2).
To investigate whether the observed results could be due
to procedural (CGH method) or analytical problems
(SpectralWare), salt extracted gDNA from whole blood
from a male patient in remission from ALL vs. gDNA from
normal male control was tested. The results of this CGH
experiment yielded only 7 duplicated and 3 deleted clones
(see Figure 3), all single clone alterations.
Discussion
The quality of wgaDNA has been primarily tested using
SNP genotyping to check the concordance between unam-
plified and amplified DNA. It has been shown that there
is little, if any, degradation in the accuracy of SNP geno-
typing with wgaDNA compared to gDNA [5]. Tzvetkov et
al. [13] performed SNP array analysis using 4 samples,
and showed that there was good concordance between
wgaDNA and gDNA, although the percentage of called
SNPs in wgaDNA samples was lower than that observed in
the gDNA. A study by Paez et al. [10] estimated that
99.82% of the genome was correctly replicated by WGA
but six regions (1q42, 4q35, 6p25, 7q36, 10q26 and
18p11) were consistently underrepresented in wgaDNA
and a further eight regions were questionable due to low
signal intensity. It has also been observed that the MDA
method results in an amplification bias that can misrepre-
sent the true number of heterozygous genotypes [7]. The
loss of heterozygous genotypes is due to one allele being
preferentially amplified in the early stages of MDA. A cer-
tain amount of sequence bias is to be expected with any
WGA method, which may result in variation in DNA qual-
ity used in the reaction, GC content, repetitive sequences
or priming efficiency. The generation of aspecific products
both in the presence of non-human DNA and even when
no DNA template is present has been observed
[14,15,18].
Sun  et al. [19] reported that in WGA products, allelic
imbalance is common when the starting material is less
than 1 ng and rarely occurs with starting material over 5
ng. Only small amounts of input material (5 ng) are
required for amplification using the GenomiPhi method
and gives an average yield of approximately 2 μg [7]. In
the current study, 200 ng of DNA was used for the WGA
reaction of the controls and was expected to yield repro-
ducible results, as previous studies testing the MDA
method have also utilised high concentrations of starting
material [20,21], but this was not our experience. How-
ever, insufficient amounts of DNA is a more commonly
reported cause of poor WGA [19].
The current study demonstrates that wgaDNA does not
result in reproducible results when compared to gDNA
from the same sample. Of the 25 variations observed in
experiment 1, 24 were in regions that have been reported
to contain a variation in a healthy control population,
indicating that they are most likely common copy number
variations. Copy number variation in a pool of DNA from
different donors are expected to be cancelled out and if
Table 1: Explanation of which samples are analysed in the different experiments.
Experiment # Description Amount of gDNA used in WGA 
reaction
Yield of WGA products (wgaDNA)
Experiment 1 gDNA (Promega): Female pool vs. male 
pool
Experiment 2 Female control: wgaDNA vs. gDNA 200 ng 2520 ng
Experiment 3 Female control: wgaDNA vs. gDNA 200 ng 3470 ng
Experiment 4 Male control: wgaDNA vs. gDNA 200 ng 3870 ng
Experiment 5 Male control: wgaDNA vs. gDNA1 200 ng 3900 ng
Experiment 6 Male ALL gDNA vs. male control gDNA2
wgaDNA is DNA amplified using GenomiPhi unless otherwise noted.
1 DNA is amplified using GenomePlex.
2 ALL patient, DNA extracted from whole blood.BMC Research Notes 2008, 1:56 http://www.biomedcentral.com/1756-0500/1/56
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Experiment 1: The two colour fluorescent dye signals are converted into intensity ratio profiles Figure 1
Experiment 1: The two colour fluorescent dye signals are converted into intensity ratio profiles. The upper and lower ratio 
threshold is 1.2 and 0.8 respectively. A) Ideogram showing all chromosomes. Differences seen between the female and male 
control (pooled gDNA from Promega) are illustrated. Gains of the X chromosome are clearly present as well as 21 duplicated 
and 6 deleted clones. Bars to the right (blue) indicate gains and to the left (red) losses. B) Chromosome 4 ratio plot. No 
deleted or duplicated clones on chromosome 4. C) Chromosome X ratio plot, a complete gain of the X chromosome can be 
seen.BMC Research Notes 2008, 1:56 http://www.biomedcentral.com/1756-0500/1/56
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single clone alterations are not deemed significant, this
could therefore be the case for experiment 1. For the pur-
pose of this study, we find it necessary to report single
clone alterations as the clinical significance of them is
unknown. In experiments 2–5 most of the significant
clones were single clone alterations, suggesting that the
observed gains and losses are relatively small in size, but
there was low reproducibility in the chromosomal loca-
tions of the observed gains and losses.
In experiments 4 and 5 two different WGA methods were
compared, which creates a possible bias, as these two
methods might not be directly comparable. The MDA
method amplifies fragments of 70 kb from the original
DNA [7], therefore it can be argued that the sonication
step is unnecessary and a source of variation of the signal
ratio. Gel electrophoresis of both sonicated gDNA and
wgaDNA showed no obvious size difference (data not
shown), this should therefore not induce the observed
alterations. Recently, it has been reported that direct label-
ling of the amplified DNA is preferred over random
primed labelling, which involves an additional amplifica-
tion of the product [22]. The additional amplification step
could cause bias and thus be a source of observed altera-
tions. Consequently, the use of random prime labelling in
this study may have led to the unusually high number of
observed alterations. As the GenomiPhi method pro-
duced high numbers of irreproducible gains and losses,
we found it necessary to test another WGA method, but
similar results were observed. In experiment 6 an ALL
sample were tested. DNA extracted from children in
remission from ALL was available for this project, so we
tested the WGA method on one of these samples. At this
stage of the study, we solely wanted to confirm that the
CGH platform is providing reproducible and reliable
results in the absence of wgaDNA, which it was.
The lack of reproducibility in the experiments in this study
was somewhat surprising since previous studies have pro-
duced favourable results. For example, Dean et al. [3]
compared wgaDNA to gDNA from the same sample, CGH
to chromosome spreads, and found that WGA does not
induce significant amplification bias. However, the sensi-
tivity of this approach would not be accurate enough to
detect differences that are identified by array CGH,
because the resolution of CGH is lower than array CGH.
The majority of array CGH studies have compared test
wgaDNA to reference wgaDNA [14,20,23], which is the
most likely explanation for the differing results. Hughes et
al. [23] have shown, by utilising Spectral Genomics BAC
arrays, that WGA does not introduce any major distortion
of imbalance of gDNA when using CGH arrays. They per-
formed control experiments corresponding to DNA
before and after amplification (gDNA vs. gDNA and
wgaDNA vs. wgaDNA) on the same sample. They also
demonstrated that DOP-PCR introduced a number of
additional copy number aberrations, while MDA intro-
duced no detectable bias [24]. In contrast, we demon-
strated that gDNA vs. wgaDNA results in bias that was
different between two experiments using the same DNA
sample, suggesting the random nature of WGA has to be
taken into account when considering this method for
array CGH analysis. Lage et al. [14] evaluated DNA ampli-
fication bias by assessing two experiments on the same
amplified samples: female gDNA vs. male gDNA and
female wgaDNA vs. male wgaDNA. Although the same
number of autosomal data points (n = 20) was observed
outside the confidence limits for both experiments [14],
there could be up to 40 differences in deletions/duplica-
tions detected since the chromosomal locations of the
observed differences in each experiment were not
reported. A number of WGA methods are available and
although it is commonly reported that WGA introduces
sequence bias, the methods are still widely used as a lot of
projects only have finite amounts of DNA available.
In conclusion, WGA appears not to be an ideal method for
increasing DNA yields for use on CGH arrays in our labo-
ratory as it creates an unacceptable amount of deletions
and duplications that are not reproducible between exper-
iments. In light of these findings, the use of both ampli-
fied test and reference DNA on CGH arrays may not
provide an accurate representation of copy number varia-
tion in DNA.
Table 2: Observed numbers of significant clones gained and lost in a dye swap experiment.
Experiment # Description Gain (n) Loss (n)
Experiment 1 gDNA (Promega): Female pool vs. male pool 21 6
Experiment 2 Female control: wgaDNA vs. gDNA 20 120
Experiment 3 Female control: wgaDNA vs. gDNA 1 69
Experiment 4 Male control: wgaDNA vs. gDNA 17 134
Experiment 5 Male control: wgaDNA vs. gDNA1 11 59
Experiment 6 Male ALL gDNA vs. male control gDNA3 73
wgaDNA is DNA amplified using GenomiPhi unless otherwise noted.
1 DNA is amplified using GenomePlex.
2 ALL patient, DNA extracted from whole blood.BMC Research Notes 2008, 1:56 http://www.biomedcentral.com/1756-0500/1/56
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Experiment 4: The two colour fluorescent dye signals are converted into intensity ratio profiles Figure 2
Experiment 4: The two colour fluorescent dye signals are converted into intensity ratio profiles. The upper and lower ratio 
threshold is 1.3 and 0.7 respectively. A) Ideogram showing all chromosomes. Differences seen between the amplified DNA 
and the non-amplified DNA in the male control are illustrated. 17 duplicated and 134 deleted clones were detected. Bars to 
the right (blue) indicate gains and to the left (red) losses.B) Chromosome 4 ratio plot. A deletion can be seen at chromosome 
4p16 and duplicated single clone alterations at location 4q13.1, 4q13-4q21, 4q28.1 and 4q32. C) Chromosome X ratio plot. A 
deletion at location Xp22.33 and duplications at Xp21.1-21.31, Xp21.1-21.32 and Xq28 can be seen.BMC Research Notes 2008, 1:56 http://www.biomedcentral.com/1756-0500/1/56
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Experiment 6: The two colour fluorescent dye signals are converted into intensity ratio profiles Figure 3
Experiment 6: The two colour fluorescent dye signals are converted into intensity ratio profiles. The upper and lower ratio 
threshold is 1.2 and 0.8 respectively. A) Ideogram showing all chromosomes. Differences seen between a male ALL patient vs. 
male control (both non-amplified DNA) are illustrated. 7 duplicated and 3 deleted clones were detected. Bars to the right 
(blue) indicate gains and to the left (red) losses. B) Chromosome 4 ratio plot, one clone duplication at 4p15.3 and one clone 
deletion at 4q35.2 can be seen. C) Chromosome X ratio plot shows two duplicated clones at locations Xp21.1 and Xq25.BMC Research Notes 2008, 1:56 http://www.biomedcentral.com/1756-0500/1/56
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